Publications by authors named "Carlo Messina"

Claim this Profile
R
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25).
Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, Marco Maruzzo, Carlo Messina, Marco Messina

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study.
Lorena Incorvaia, Mattia Puglisi, Marco Maruzzo, Giulia Mammone, Orazio Caffo, Carlo Messina

Oncologist· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Management of Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.
Antonio Cigliola, Brigida Anna Maiorano, Doga Dengur, Valentina Tateo, Chiara Mercinelli, Carlo Messina

Cancers (Basel)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Best therapeutic approach in metastatic hormone-sensitive prostate cancer based on disease volume: a systematic review and network meta-analysis.
Fabrizio Di Costanzo, Chiara Mercinelli, Alessio Signori, Carlo Messina, Vincenza Conteduca

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereotactic Body Radiotherapy for the Treatment of Oligometastases Located in the Peritoneum or in the Abdominal Wall: Preliminary Results from a Mono-Institutional Analysis.
Francesco Cuccia, Salvatore D'Alessandro, Marina Campione, Vanessa Figlia, Gianluca Mortellaro, Carlo Messina

J Pers Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.
Matteo Santoni, Thomas Büttner, Pasquale Rescigno, Ondrej Fiala, Nicolò Cavasin, Carlo Messina

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, Linda Cerbone, Ondrej Fiala, Carlo Messina

Cancer Immunol Immunother· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2 Study.
Ondřej Fiala, Francesco Massari, Umberto Basso, Patrizia Giannatempo, Enrique Grande, Carlo Messina

Target Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
Alessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, Francesco Massari, Se Hoon Park, Carlo Messina

Target Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).
Elisabetta Gambale, Marco Maruzzo, Carlo Messina, Irene De Gennaro Aquino, Ismaela Anna Vascotto, Marco Messina

Clin Genitourin Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites?
Mauro Francesco Pio Maiorano, Carlo Messina, Evaristo Maiello, Gennaro Cormio, Brigida Anna Maiorano

BJOG· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, Francesco Massari, Renate Pichler, Carlo Messina

Target Oncol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice.
Pierpaolo Alongi, Marco Messina, Alessio Pepe, Annachiara Arnone, Viola Vultaggio, Carlo Messina

Nucl Med Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.
Carlo Messina, Martina Catalano, Giandomenico Roviello, Annalice Gandini, Marco Maruzzo, Marco Messina

Cancer Immunol Immunother· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).
Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Sebastiano Buti, Giuseppe Procopio, Carlo Messina

BMC Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Carlo Messina, Emilio Francesco Giunta, Alessio Signori, Sara Elena Rebuzzi, Giuseppe Luigi Banna

Eur Urol Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Carlo Messina

Cancer Immunol Immunother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors.
Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Carlo Messina

Cancers (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, Marco Maruzzo, Roberto Iacovelli, Carlo Messina

Eur Urol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Yohei Okada, Francesco Massari, Carlo Messina

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Matteo Santoni, Francesco Massari, Zin W Myint, Roberto Iacovelli, Martin Pichler, Carlo Messina

Clin Genitourin Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis.
Andrés J M Ferreri, Pier Luigi Zinzani, Carlo Messina, Diletta Valsecchi, Maria Chiara Rendace

Cancers (Basel)· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, Zin W Myint, Nicolò Cavasin, Carlo Messina

Minerva Urol Nephrol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Matteo Santoni, Francesco Massari, Zin W Myint, Roberto Iacovelli, Martin Pichler, Carlo Messina

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
Joris van de Haar, Xuhui Ma, Salo N Ooft, Pim W van der Helm, Louisa R Hoes, Carlo Messina

Nat Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis